Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Health Promot Int ; 36(6): 1716-1726, 2021 Dec 23.
Artículo en Inglés | MEDLINE | ID: mdl-34002217

RESUMEN

In India, strict public health measures to suppress COVID-19 transmission and reduce burden have been rapidly adopted. Pandemic containment and confinement measures impact societies and economies; their costs and benefits must be assessed holistically. This study provides an evolving portrait of the health, economic and social consequences of the COVID-19 pandemic on vulnerable populations in India. Our analysis focuses on 100 days early in the pandemic from 13 March to 20 June 2020. We developed a conceptual framework based on the human right to health and the UN Sustainable Development Goals (SDGs). We analysed people's experiences recorded and shared via mobile phone on the voice platforms operated by the Gram Vaani COVID-19 response network, a service for rural and low-income populations now being deployed to support India's COVID-19 response. Quantitative and visual methods were used to summarize key features of the data and explore relationships between factors. In its first 100 days, the platform logged over 1.15 million phone calls, of which 793 350 (69%) were outbound calls related largely to health promotion in the context of COVID-19. Analysis of 6636 audio recordings by network users revealed struggles to secure the basic necessities of survival, including food (48%), cash (17%), transportation (10%) and employment or livelihoods (8%). Themes were mapped to shortfalls in 10 SDGs and their associated targets. Pre-existing development deficits and weak social safety nets are driving vulnerability during the COVID-19 crisis. For an effective pandemic response and recovery, these must be addressed through inclusive policy design and institutional reforms.


Asunto(s)
COVID-19 , Pandemias , Humanos , India , SARS-CoV-2 , Desarrollo Sostenible
2.
J Tradit Complement Med ; 7(1): 94-98, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-28053893

RESUMEN

Bryophytes are the second largest group of land plants after angiosperms. There is very less knowledge available about medicinal properties of these plants. Bryophytes are popular remedy among the tribal people of different parts of the world. Tribal people use these plants to cure various ailments in their daily lives. Bryophytes are used to cure hepatic disorders, skin diseases, cardiovascular diseases, used as antipyretic, antimicrobial, wound healing and many more other ailments by different tribal communities of Africa, America, Europe, Poland, Argentina, Australia, New Zealand, Turkey, Japan, Taiwan, Pakistan, China, Nepal and different parts of South, North and Eastern India. Apart from ethno-medicinal uses some bryophytes possesses antitumor activities against different cancer cell lines and this property of bryophytes needs to be more focused in the future. Compile information about medicinal properties and anticancer properties of bryophytes is lacking till date. In the present review, the authors tried to compile all the ethno-medicinal and other related information of bryophytes and fill the knowledge lacuna in this particular field. Some published reviews are available but the information is segregated. This manuscript will help people doing research in the bryophytes.

3.
Oncoimmunology ; 5(1): e1049802, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26942057

RESUMEN

Interleukin-6, a cytokine produced particularly by triple-negative breast cancers, strongly inhibits T cell responses in the tumor microenvironment. Here we tested cryoablation combined with Meriva (a lecithin delivery system of curcumin with improved bioavailability) in mice with metastatic breast cancer (4T1). Cryoablation involves killing of tumor cells through freezing and thawing, resulting in recruitment of tumor-specific T cells, while curcumin stimulates T cells through the reduction of IL-6 in the TME. Cryoablation plus Meriva accumulated and activated CD8+ T cells to multiple tumor-associated antigens such as Mage-b and Survivin (both expressed by 4T1 tumors). This correlated with a nearly complete reduction of 4T1 primary tumors and lung metastases while little effect was observed from saline or Meriva alone (28 d after tumor cell injection). The survival rate in the group of cryoablation plus Meriva was significantly improved compared to all control groups. Using a less aggressive 4T1 model expressing luciferase (4T1.2luc3), we demonstrated that all mice receiving saline or Meriva developed metastases in the lungs and a primary tumor (38 d after tumor cell injection; and died soon after that), but not the mice receiving cryoablation or cryoablation plus Meriva. However, on day 58 the mice receiving cryoablation developed 4T1.2luc3 metastases in the lungs, while mice receiving cryoablation plus Meriva were free of metastases. These results strongly suggest that cryoablation delayed the development of lung metastases on the short-term, but Meriva administered after cryoablation was significantly better in delaying the development of lung metastases and survival on the long-term.

4.
Exp Parasitol ; 151-152: 1-7, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25655406

RESUMEN

A full-length complementary DNA (cDNA) encoding Cu/Zn-superoxide dismutase was isolated from Fasciola gigantica that on nucleotide sequencing showed a close homology (98.9%) with Cu/Zn-superoxide dismutase (SOD) of the temperate liver fluke, F. hepatica. Expression of the gene was found in all the three developmental stages of the parasite viz. adult, newly excysted juvenile and metacercaria at transcriptional level by reverse transcription-polymerase chain reaction (RT-PCR) and at the protein level by Western blotting. F. gigantica Cu/Zn-SOD cDNA was cloned and expressed in Escherichia coli. Enzyme activity of the recombinant protein was determined by nitroblue tetrazolium (NBT)-polyacrylamide gel electrophoresis (PAGE) and this activity was inactivated by hydrogen peroxide but not by sodium azide, indicating that the recombinant protein is Cu/Zn-SOD. The enzyme activity was relatively stable at a broad pH range of pH 4.0-10.0. Native Cu/Zn-superoxide dismutase protein was detected in the somatic extract and excretory-secretory products of the adult F. gigantica by Western blotting. NBT-PAGE showed a single Cu/Zn-SOD present in the somatic extract while three SODs are released ex vivo by the adult parasite. The recombinant superoxide dismutase did not react with the serum from buffaloes infected with F. gigantica. The role of this enzyme in defense by the parasite against the host reactive oxygen species is discussed.


Asunto(s)
ADN Complementario/aislamiento & purificación , Fasciola/enzimología , Regulación Enzimológica de la Expresión Génica , Superóxido Dismutasa/aislamiento & purificación , Mataderos , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Western Blotting , Búfalos/parasitología , ADN Complementario/química , ADN de Helmintos/química , ADN de Helmintos/aislamiento & purificación , Electroforesis en Gel de Poliacrilamida , Fasciola/genética , Fasciola/crecimiento & desarrollo , Fasciola hepatica/enzimología , Fasciola hepatica/genética , Fascioliasis/parasitología , Fascioliasis/veterinaria , Concentración de Iones de Hidrógeno , Indicadores y Reactivos , Estadios del Ciclo de Vida/genética , Nitroazul de Tetrazolio , ARN de Helminto/genética , ARN de Helminto/aislamiento & purificación , Conejos , Proteínas Recombinantes/química , Análisis de Secuencia de ADN , Superóxido Dismutasa/química , Superóxido Dismutasa/genética
5.
Cancer Med ; 2(4): 571-82, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24156030

RESUMEN

Success of cancer vaccination is strongly hampered by immune suppression in the tumor microenvironment (TME). Interleukin (IL)-6 is particularly and highly produced by triple-negative breast cancer (TNBC) cells, and has been considered as an important contributor to immune suppression in the TME. Therefore, we hypothesized that IL-6 reduction may improve efficacy of vaccination against TNBC cancer through improved T-cell responses. To prove this hypothesis, we investigated the effect of curcumin, an inhibitor of IL-6 production, on vaccination of a highly attenuated Listeria monocytogenes (Listeria(at)), encoding tumor-associated antigens (TAA) Mage-b in a TNBC model 4T1. Two therapeutic vaccination strategies with Listeria(at)-Mage-b and curcumin were tested. The first immunization strategy involved all Listeria(at)-Mage-b vaccinations and curcumin after tumor development. As curcumin has been consumed all over the world, the second immunization strategy involved curcumin before and all therapeutic vaccinations with Listeria(at)-Mage-b after tumor development. Here, we demonstrate that curcumin significantly improves therapeutic efficacy of Listeria(at)-Mage-b with both immunization strategies particularly against metastases in a TNBC model (4T1). The combination therapy was slightly but significantly more effective against the metastases when curcumin was administered before compared to after tumor development. With curcumin before tumor development in the combination therapy, the production of IL-6 was significantly decreased and IL-12 increased by myeloid-derived suppressor cells (MDSC), in correlation with improved CD4 and CD8 T-cell responses in blood. Our study suggests that curcumin improves the efficacy of Listeria(at)-Mage-b vaccine against metastases in TNBC model 4T1 through reversal of tumor-induced immune suppression.


Asunto(s)
Antineoplásicos/farmacología , Vacunas Bacterianas/inmunología , Curcumina/farmacología , Listeria monocytogenes/inmunología , Neoplasias Mamarias Experimentales , Subgrupos de Linfocitos T/inmunología , Neoplasias de la Mama Triple Negativas/inmunología , Neoplasias de la Mama Triple Negativas/terapia , Animales , Antineoplásicos/administración & dosificación , Apoptosis/efectos de los fármacos , Apoptosis/inmunología , Vacunas Bacterianas/administración & dosificación , Vacunas contra el Cáncer/administración & dosificación , Vacunas contra el Cáncer/inmunología , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Curcumina/administración & dosificación , Modelos Animales de Enfermedad , Femenino , Inmunización , Interleucina-12/biosíntesis , Interleucina-6/biosíntesis , Ratones , Células Mieloides/efectos de los fármacos , Células Mieloides/inmunología , Células Mieloides/metabolismo , Metástasis de la Neoplasia , Subgrupos de Linfocitos T/metabolismo , Neoplasias de la Mama Triple Negativas/patología
6.
Parasitol Res ; 110(1): 419-26, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21750874

RESUMEN

Fasciola gigantica, causative agent of tropical fasciolosis, inflicts substantial economic losses on the livestock industry, affecting severely buffalo productivity in the tropical countries. Very few vaccination trials with different target antigens against F. gigantica infection have been conducted in this host. Present study describes a vaccination trial in buffaloes with F. gigantica recombinant glutathione S-transferase and fatty acid binding protein. The two recombinant proteins were expressed in Escherichia coli and evaluated for their immunoprophylactic potential in buffalo calves, using montanide 70 M-VG, a mineral oil-based adjuvant, for delivering the antigens. Buffalo calves were distributed in three groups, with group I, II and III calves immunized with recombinant glutathione S-transferase, fatty acid binding protein and a cocktail of these two antigens, respectively. Immunization of the calves evoked a mixed IgG1 and IgG2 antibody response. Present vaccination trial in these animals achieved a maximum protection level of 35%, when the two antigens were used in combination. Eosinophils were measured in both immunized and non-immunized challenge control animals, which showed a steady increase in their count in response to immunization with both the antigens and infection with F. gigantica, respectively.


Asunto(s)
Antígenos Helmínticos/inmunología , Fascioliasis/veterinaria , Proteínas de Unión a Ácidos Grasos/inmunología , Glutatión Transferasa/inmunología , Vacunación/métodos , Adyuvantes Inmunológicos/administración & dosificación , Animales , Anticuerpos Antihelmínticos/sangre , Antígenos Helmínticos/administración & dosificación , Búfalos , Eosinófilos/inmunología , Escherichia coli/genética , Fascioliasis/prevención & control , Proteínas de Unión a Ácidos Grasos/administración & dosificación , Glutatión Transferasa/administración & dosificación , Inmunoglobulina G/sangre , Recuento de Leucocitos , Proteínas Recombinantes/genética , Proteínas Recombinantes/inmunología , Vacunas de Subunidad/administración & dosificación , Vacunas de Subunidad/inmunología , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA